Component

LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012

Context-specific entity; species, compartment and exposure are stated on each claim.

5 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Lovastatin flux across Caco-2 monolayers was higher with the three product extracts than with pure lovastatin at a matched 25 micromolar concentration.

    LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012 → Human Caco-2 apical-to-basolateral lovastatin flux source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Human intestinal-cell-line model.
    limitations
    Does not quantify intestinal absorption or oral bioavailability in humans.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    A cell-layer transport result supported a mixture effect.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 140–146

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human intestinal-cell-line model. · source_derived_draft · unverified_draft

    ## red-yeast-rice-extract-caco2-flux A cell-layer transport result supported a mixture effect. Lovastatin flux across Caco-2 monolayers was higher with the three product extracts than with pure lovastatin at a matched 25 micromolar concentration. Model: Human intestinal-cell-line model. Limitations: Does not quantify intestinal absorption or oral bioavailability in humans. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  2. The three 2012 red yeast rice product extracts inhibited human microsomal CYP1A2 more potently than pure lovastatin at matched nominal lovastatin concentrations.

    LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012 → Human cytochrome P450 1A2 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969, CYP methods and results
    experimental_model
    Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system.
    limitations
    In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The mixture changed an enzyme assay beyond its lovastatin content.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 108–114

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. · source_derived_draft · unverified_draft

    ## red-yeast-rice-extract-cyp1a2 The mixture changed an enzyme assay beyond its lovastatin content. The three 2012 red yeast rice product extracts inhibited human microsomal CYP1A2 more potently than pure lovastatin at matched nominal lovastatin concentrations. Model: Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. Limitations: In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified. Evidence access: Primary full text PMC3513969, CYP methods and results [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  3. The three 2012 red yeast rice product extracts inhibited human microsomal CYP2C19 more potently than pure lovastatin at matched nominal lovastatin concentrations.

    LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012 → Human cytochrome P450 2C19 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969, CYP methods and results
    experimental_model
    Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system.
    limitations
    In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The mixture changed an enzyme assay beyond its lovastatin content.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 116–122

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. · source_derived_draft · unverified_draft

    ## red-yeast-rice-extract-cyp2c19 The mixture changed an enzyme assay beyond its lovastatin content. The three 2012 red yeast rice product extracts inhibited human microsomal CYP2C19 more potently than pure lovastatin at matched nominal lovastatin concentrations. Model: Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. Limitations: In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified. Evidence access: Primary full text PMC3513969, CYP methods and results [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  4. The three 2012 red yeast rice product extracts inhibited human microsomal CYP3A4 more potently than pure lovastatin at matched nominal lovastatin concentrations.

    LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012 → Human cytochrome P450 3A4 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969, CYP methods and results
    experimental_model
    Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system.
    limitations
    In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The mixture changed an enzyme assay beyond its lovastatin content.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 124–130

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. · source_derived_draft · unverified_draft

    ## red-yeast-rice-extract-cyp3a4 The mixture changed an enzyme assay beyond its lovastatin content. The three 2012 red yeast rice product extracts inhibited human microsomal CYP3A4 more potently than pure lovastatin at matched nominal lovastatin concentrations. Model: Human liver microsomes; product concentrations normalized to 0.5–25 micromolar lovastatin, with an NADPH-generating system. Limitations: In-vitro inhibition is not a measured interaction with every drug using this enzyme; the additional responsible constituent was not identified. Evidence access: Primary full text PMC3513969, CYP methods and results [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  5. The three product extracts inhibited P-glycoprotein transport activity more potently than pure lovastatin in the study assay.

    LipoCol Forte, Xuezhikang and Cholestin extract panel studied in 2012 → Human P-glycoprotein / ABCB1 / MDR1 source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Canine MDCK cells engineered with human MDR1; radiolabeled digoxin probe.
    limitations
    Human transporter in a canine host cell; not a clinical digoxin-interaction magnitude.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    An efflux transporter provides another exposure-related route.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 132–138

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Canine MDCK cells engineered with human MDR1; radiolabeled digoxin probe. · source_derived_draft · unverified_draft

    ## red-yeast-rice-extract-pgp An efflux transporter provides another exposure-related route. The three product extracts inhibited P-glycoprotein transport activity more potently than pure lovastatin in the study assay. Model: Canine MDCK cells engineered with human MDR1; radiolabeled digoxin probe. Limitations: Human transporter in a canine host cell; not a clinical digoxin-interaction magnitude. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards